Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.70 |
| ▸ | TNF | P01375 | 6/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825616 | 0.94 | TNF (0.73) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6097184 | 0.91 | TNF (0.72) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL21494454 | 0.91 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4919857 | 0.90 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3128437 | 0.90 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4847349 | 0.90 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098976 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537314 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098437 | 0.89 | PDE4B (0.60) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6096863 | 0.89 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091356-B2 | Substituted alkanohydroxamic acids and method of reducing TNFα levels | CELGENE CORPORATION | 2006-08-15 | — | — | US | claimed |
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2004-01-08 | — | — | US | claimed |
| US-6656964-B2 | Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases | CELGENE CORPORATION | 2003-12-02 | — | — | US | claimed |
| EP-1035848-B1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2003-04-23 | — | — | EP | claimed |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | CALGENE CORPORATION | 2001-12-06 | — | — | US | claimed |
| EP-1035848-A4 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2001-05-23 | — | — | EP | claimed |
| US-6214857-B1 | REDUCES TUMOR NECROSIS FACTOR LEVELS | CELGENE CORPORATION | 2001-04-10 | — | — | US | claimed |
| EP-1035848-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 2000-09-20 | — | — | EP | claimed |
| WO-1999006041-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | disclosed |
| US-7345062-B2 | Substituted acylhydroxamic acids and method of reducing TNFαlevels | CELGENE CORPORATION (US) | 2008-03-18 | — | — | US | disclosed |
| US-7091356-B2 | Substituted alkanohydroxamic acids and method of reducing TNFα levels | CELGENE CORPORATION | 2006-08-15 | — | — | US | disclosed |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE | 2004-08-26 | — | — | US | disclosed |
| US-6699899-B1 | ISOINDOLE DERIVATIVES; ANTIINFLAMMATORY, ANTIPYRETIC, AND ANTICOAGULANT AGENTS | CELGENE CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | CALGENE CORPORATION | 2001-12-06 | — | — | US | disclosed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1035848-A4 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6214857-B1 | REDUCES TUMOR NECROSIS FACTOR LEVELS | CELGENE CORPORATION | 2001-04-10 | — | — | US | disclosed |
| EP-1035848-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999006041-A1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | APEH, TNF, ACOX3 | PDE4A 30/4885PDE4B 70/4885PDE4C 53/4885 |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | TNF, APEH, ACOX3 | PDE4A 14/4885PDE4B 42/4885PDE4C 30/4885 |
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | TNF, TNFRSF1A, LTA | PDE4A 10/4885PDE4B 54/4885PDE4C 37/4885 |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | PDE3A, PDE2A, PDE3B | PDE4A 6/4885PDE4B 15/4885PDE4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.